Aurinia Pharmaceuticals AUPH Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $298.3M+20.6% | $283.06M+20.4% | $265.81M+20.6% | $260.11M+25.6% | $247.3M+29.2% | ||
| $30.6M+5.2% | $32.67M+15.6% | $29.42M+4.7% | $27.28M-5.4% | $29.07M+35.3% | ||
| $267.7M+22.7% | $250.39M+21.0% | $236.39M+22.9% | $232.84M+30.6% | $218.23M+28.4% | ||
| 89.7%+1.5pp | 88.5%+0.5pp | 88.9%+1.7pp | 89.5%+3.4pp | 88.2%-0.5pp | ||
| $34.23M+63.2% | $32.51M+56.4% | $29.72M+29.7% | $24.33M-27.3% | $20.98M-50.1% | ||
| $103.48M-28.5% | $101.79M-40.8% | $109.57M-40.8% | $125.76M-34.0% | $144.67M-24.9% | ||
| $19.41M-0.2% | $19.45M0.0% | $19.45M+11.2% | $19.48M+25.5% | $19.45M+43.2% | ||
| $114K-99.4% | $1.65M-92.9% | $17M+119% | $17M+119% | $17.96M+169% | ||
| —— | —— | -$10.1M-9.4% | -$13.74M-88.2% | -$4.21M-6.1% | ||
| $173.81M-19.9% | $178.14M-25.7% | $195.8M-22.6% | $208.1M-22.3% | $216.88M-18.7% | ||
| $124.49M+309% | $104.91M+2,338% | $70.01M+314% | $52.01M+186% | $30.41M+140% | ||
| 41.7%+29.4pp | 37.1%+39.1pp | 26.3%+41.2pp | 20%+49.3pp | 12.3%+51.7pp | ||
| $4.28M-7.4% | $4.33M-10.4% | $4.43M-11.4% | $4.54M-12.6% | $4.62M+13.8% | ||
| $13.52M-15.6% | $13.57M-20.0% | $14.06M-19.9% | $15.01M-15.6% | $16.01M— | ||
| $133.73M+220% | $114.16M+1,433% | $79.64M+495% | $62.49M+230% | $41.81M+168% | ||
| -$164.48M— | -$173.05M— | —— | —— | —— | ||
| $298.21M+648% | $287.2M+4,893% | $77.84M+445% | $60.64M+220% | $39.85M+164% | ||
| 100%+83.9pp | 101.5%+99.0pp | 29.3%+39.5pp | 23.3%+47.6pp | 16.1%+48.8pp | ||
| $2.17+675% | $2.08+4,060% | $0.56+473% | $0.43+226% | $0.28+165% | ||
| $2.26+679% | $2.17+4,240% | $0.58+487% | $0.44+229% | $0.29+167% | ||
| 549.9M-5.1% | 555.4M-4.2% | 562.9M-2.4% | 572.6M-0.3% | 579.2M+1.1% | ||
| 533.4M-6.1% | 540M-5.8% | 548.7M-4.4% | 559.9M-2.4% | 568.4M-0.8% | ||
| $298.16M+648% | $287.25M+4,823% | $77.47M+452% | $60.59M+221% | $39.87M+164% | ||
| —— | —— | -$10.1M-9.4% | -$13.74M-88.2% | -$4.21M-6.1% | ||
| $298.3M+20.6% | $283.06M+20.4% | $265.81M+20.6% | $260.11M+25.6% | $247.3M+29.2% | ||
| $124.49M+309% | $104.91M+2,338% | $70.01M+314% | $52.01M+186% | $30.41M+140% | ||
| $143.9M+189% | $124.36M+743% | $89.45M+689% | $71.48M+258% | $49.87M+181% | ||
| $143.9M+189% | $124.36M+743% | $89.45M+689% | $71.48M+258% | $49.87M+181% | ||
| 48.2%+28.1pp | 43.9%+37.7pp | 33.7%+40.5pp | 27.5%+49.3pp | 20.2%+52.4pp | ||
| $124.49M+309% | $104.91M+2,338% | $70.01M+314% | $52.01M+186% | $30.41M+140% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aurinia Pharmaceuticals's revenue?
- Aurinia Pharmaceuticals (AUPH) generated $298.3M in revenue over the trailing twelve months, up 20.6% year over year.
- Is Aurinia Pharmaceuticals profitable?
- Aurinia Pharmaceuticals reported $298.2M in net income over the trailing twelve months, a 100.0% net margin.
- What are Aurinia Pharmaceuticals's profit margins?
- Gross margin is 89.7% and operating margin is 41.7%, with a 100.0% net margin.
- What is Aurinia Pharmaceuticals's earnings per share?
- Aurinia Pharmaceuticals's diluted EPS over the trailing twelve months is $2.17.
- Where does Aurinia Pharmaceuticals's income statement data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
